AR062210A1 - Pirazolopirimidinas sustituidas, un proceso para su preparacion y su uso como medicamento - Google Patents
Pirazolopirimidinas sustituidas, un proceso para su preparacion y su uso como medicamentoInfo
- Publication number
- AR062210A1 AR062210A1 ARP070103439A ARP070103439A AR062210A1 AR 062210 A1 AR062210 A1 AR 062210A1 AR P070103439 A ARP070103439 A AR P070103439A AR P070103439 A ARP070103439 A AR P070103439A AR 062210 A1 AR062210 A1 AR 062210A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkylaminocarbonyl
- alkylamino
- alkyl
- heterocyclyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Moduladores de mGluR5 para la prevencion de trastornos neurologicos agudos y cronicos. Proceso de obtencion y composiciones farmacéuticas que los comprende. Reivindicacion 1: Un compuesto pirazolopirimidínico de formula (1) donde, Y1 representa N o C-, Y2 representa N o C-, Y3 representa N o C-, Y4 representa N o C-, mediante la cual al menos dos de los grupos Y1 a Y4 denotan un átomo de carbono, R1 representa cloro o bromo; R2 y R3 cada uno independientemente representa hidrogeno, alquilo C1- 6, cicloalquilo C3-7 o trifluorometilo; o R2 y R3 ambos junto con el átomo de carbono del anillo representan un grupo carbonilo; R4 y R5 cada uno independientemente representa hidrogeno, alquilo C1-6, cicloalquilo C3-7 o trifluorometilo; o R4 y R5 ambos junto con el átomo de carbono del anillo representan un grupo carbonilo; R6 y R7 representan independientemente hidrogeno, alquilo C1-6, cicloalquilo C3-7 o trifluorometilo; o R6 y R7 ambos junto con el átomo de carbono del anillo representan un grupo carbonilo; R2 o R3 junto con R6 y R7 también pueden formar un radical bivalente a partir del grupo CH2-CH2 o CH2-O; R10 y R11 representan independientemente hidrogeno, halogeno, amino, hidroxi, nitro, ciano, trifluorometilo, trifluorometoxi, arilo, alquilo C1-6, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, cicloalquiloxi C3-7, alqueniloxi C2-6, alquiniloxi C2-6, heteroarilo, heterociclilo, ariloxi, heteroariloxi, heterocicliloxi, alquilamino C1-6, di- alquilamino C1-6, cicloalquilamino C3-7, di-cicloalquilamino C3-7, alquil C1-6-cicloalquilamino C3-7, alquenilamino C2-6, alquinilamino C2-6, di-alquenilamino C2-6, di-alquinilamino C2-6, alquil C1-6-alquenilamino C2-6, alquil C1-6-alquinilamino C2- 6, alquenil C2-6-cicloalquilamino C3-7, alquinil C2-6-cicloalquilamino C3-7, alquenil C2-6-alquinilamino C2-6, arilamino, diarilamino, aril-alquilamino C1-6, aril-alquenilamino C2-6, aril-alquinilamino C2-6, aril-cicloalquilamino C3-7, heteroarilamino, diheteroarilamino, heteroaril-alquilamino C1-6, heteroaril-alquenilamino C2-6, heteroaril-alquinilamino C2-6, heteroaril-cicloalquilamino C3-7, heteroarilarilamino, heterociclilamino, diheterociclilamino, heterociclil-alquilamino C1- 6, heterociclil-alquenilamino C2-6, heterociclil-alquinilamino C2-6, heterociclil-cicloalquilamino C3-7, heterociclilarilamino, heterociclilhetero-arilamino, acilo, aciloxi, acilamino, alcoxicarbonilo C1-6, cicloalcoxi C3-7-carbonilo, alqueniloxicarbonilo C2-6, alquiniloxicarbonilo C2-6, ariloxicarbonilo, heteroariloxicarbonilo, heterocicliloxicarbonilo, aminocarbonilo, alquilamino C1-6-carbonilo, di-alquilaminocarbonilo C1-6, cicloalquilaminocarbonilo C3-7, di- cicloalquilaminocarbonilo C3-7, alquil C1-6-cicloalquilaminocarbonilo C3-7, alquenil C2-6-aminocarbonjlo, alquinilaminocarbonilo C2-6, di-alquenilaminocarbonilo C2-6, di-alquinilaminocarbonilo C2-6, alquil C1-6-alquenilaminocarbonilo C2-6, alquil C1- 6-alquinil C2-6-aminocarbonilo, alquenil C2-6-cicloalquilaminocarbonilo C3-7, alquinil C2-6-cicloalquilaminocarbonilo C3-7, alquenil C2-6-alquinilaminocarbonilo C2-6, arilaminocarbonilo, diarilaminocarbonilo, aril-alquilaminocarbonilo C1-6, aril- alquenilaminocarbonilo C2-6, aril-alquinilaminocarbonilo C2-6, aril-cicloalquilaminocarbonil C3-7 heteroarilaminocarbonilo, diheteroarilaminocarbonilo, heteroaril-alquilaminocarbonilo C1-6, heteroaril-alquenilaminocarbonilo C2-6, heteroaril- alquinilaminocarbonilo C2-6, heteroaril-cicloalquilaminocarbonilo C3-7, heteroarilarilaminocarbonilo, heterociclilaminocarbonilo, diheterociclilaminocarbonilo, heterociclil-alquilaminocarbonilo C1-6, heterociclil-alquenilamino C2-6-carbonilo, heterociclil-alquinilaminocarbonilo C2-6, heterociclil-cicloalquil C3-7-aminocarbonilo, heterociclilarilaminocarbonilo, heterociclilheteroarilaminocarbonilo, alquilsulfinilo C1-6, cicloalquilsulfinilo C3-7, alquenilsulfinilo C2-6, alquinilsulfinilo C2-6, arilsulfinilo, heteroarilsulfinilo, heterociclilsulfinilo, alquilsulfonilo C1-6, cicloalquilsulfonilo C3-7, alquenilsulfonilo C2-6, alquinilsulfonilo C2-6, arilsulfonilo, heteroarilsulfonilo, heterociclilsulfonilo, alquilsulfonilamino C1-6, o arilsulfonilamino; o R10 y R11 junto con los dos átomos de carbono que los portan representan un heteroarilo que posee 5 o 6 miembros de anillo o un grupo heterociclilo que posee 5 o 6 miembros de anillo, que pueden ser sustituidos con uno de los siguientes grupos: halogeno, hidroxi, nitro, ciano, trifluorometilo, trifluorometoxi, alquilo C1-6 y alcoxi C1-6; e isomeros opticos, sales, hidratos, solvatos y polimorfos aceptables para uso farmacéutico de los mismos, con la condicion que el compuesto de formula (1) no representa al compuesto (6-Bromo-pirazolo[1,5-a]pirimidin-2-il)-(3,4-dihidro-1H-isoquinolin-2-il)-metanona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83582006P | 2006-08-04 | 2006-08-04 | |
US87754406P | 2006-12-28 | 2006-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062210A1 true AR062210A1 (es) | 2008-10-22 |
Family
ID=38710494
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103438A AR062209A1 (es) | 2006-08-04 | 2007-08-03 | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. |
ARP070103437A AR063680A1 (es) | 2006-08-04 | 2007-08-03 | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. |
ARP070103439A AR062210A1 (es) | 2006-08-04 | 2007-08-03 | Pirazolopirimidinas sustituidas, un proceso para su preparacion y su uso como medicamento |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103438A AR062209A1 (es) | 2006-08-04 | 2007-08-03 | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. |
ARP070103437A AR063680A1 (es) | 2006-08-04 | 2007-08-03 | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. |
Country Status (21)
Country | Link |
---|---|
US (4) | US7947689B2 (es) |
EP (3) | EP2054421B1 (es) |
JP (2) | JP2009545569A (es) |
KR (1) | KR20090047450A (es) |
AR (3) | AR062209A1 (es) |
AT (2) | ATE494289T1 (es) |
AU (2) | AU2007280428B2 (es) |
BR (2) | BRPI0714766A2 (es) |
CA (2) | CA2659871A1 (es) |
CY (1) | CY1112003T1 (es) |
DE (2) | DE602007011773D1 (es) |
DK (1) | DK2054416T3 (es) |
HR (1) | HRP20110128T1 (es) |
IL (2) | IL196008A0 (es) |
MX (2) | MX2009000919A (es) |
PL (1) | PL2054416T3 (es) |
PT (1) | PT2054416E (es) |
RU (2) | RU2450004C2 (es) |
TW (3) | TW200823215A (es) |
WO (3) | WO2008015270A1 (es) |
ZA (1) | ZA200810605B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008056176A1 (en) * | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
HK1136565A1 (en) * | 2007-03-31 | 2010-07-02 | Intervet Int Bv | Processes for making zilpaterol and salts thereof |
EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
CN103212078A (zh) | 2008-06-30 | 2013-07-24 | 诺瓦提斯公司 | 用于治疗帕金森病的包含mGluR调节剂的组合产品 |
EP2504340A1 (en) | 2009-11-25 | 2012-10-03 | Merz Pharma GmbH & Co. KGaA | Crystalline forms of substituted pyrazolopyrimidines |
CA2820262A1 (en) | 2010-12-08 | 2012-06-14 | Vanderbilt University | Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors |
CA2830220A1 (en) * | 2011-03-15 | 2012-09-20 | Vanderbilt University | Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors |
US8865725B2 (en) | 2011-03-15 | 2014-10-21 | Vanderbilt University | Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors |
WO2012139876A1 (en) | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2013087815A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof |
WO2013087808A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin |
US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9029360B2 (en) * | 2012-03-29 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
US20150218103A1 (en) | 2012-08-25 | 2015-08-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
ES2619708T3 (es) | 2013-03-13 | 2017-06-26 | VIIV Healthcare UK (No.5) Limited | Inhibidores de la replicación del virus de inmunodeficiencia humana |
CN105189511B (zh) | 2013-03-13 | 2017-05-24 | 百时美施贵宝公司 | 人免疫缺陷病毒复制的抑制剂 |
JP6268656B2 (ja) | 2013-03-14 | 2018-01-31 | ビーブ・ヘルスケア・ユーケイ・(ナンバー5)・リミテッドViiV Healthcare UK (No.5) Limited | ヒト免疫不全ウイルス複製の阻害剤 |
WO2014197536A2 (en) | 2013-06-04 | 2014-12-11 | Temple University Of The Commonwealth | Novel beta lactams as modulators of glutamate uptake and methods for use thereof |
US10398142B2 (en) | 2013-11-05 | 2019-09-03 | Temple University Of The Commonwealth System Of Higher Education | Polycationic amphiphiles as antimicrobial agents |
US10136639B2 (en) | 2013-11-05 | 2018-11-27 | Villanova University | Polycationic amphiphiles as antimicrobial agents |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
AP2017009744A0 (en) | 2014-08-06 | 2017-02-28 | Pfizer | Imidazopyridazine compounds |
UA125463C2 (uk) | 2016-01-27 | 2022-03-16 | Універсітет Цюріх | ЗАСТОСУВАННЯ МОДУЛЯТОРІВ GABA<sub>A</sub>-РЕЦЕПТОРА ДЛЯ ЛІКУВАННЯ СВЕРБЕЖУ |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA974518A (en) | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US3988339A (en) * | 1974-02-08 | 1976-10-26 | Smithkline Corporation | Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase |
US3974283A (en) * | 1974-03-18 | 1976-08-10 | Sandoz, Inc. | N-substituted-4-T-butyl-1-pyridinethiocarboxamides and their use for treatment of inflammation or pain |
NZ190915A (en) * | 1978-07-31 | 1984-07-31 | Hoffmann La Roche | Oxadiazolotriazine derivatives and pharmaceutical compositions |
DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
SU768177A1 (ru) * | 1979-04-23 | 1985-08-07 | МГУ им.М.В.Ломоносова | Способ получени ( @ )-(-) или ( @ )-(+)-1=метил-1,2,3,4-тетрагидроизохинолина |
ZA803591B (en) * | 1979-07-09 | 1981-06-24 | American Cyanamid Co | Substituted pyrazolo(1,5-a)pyrimidines |
US4340597A (en) * | 1981-04-13 | 1982-07-20 | Schering Corporation | 1-Substituted-4-aryl-1,2,5,6-tetrahydro and hexahydropyridines |
DE3308554A1 (de) * | 1983-03-10 | 1984-09-13 | Hoechst Ag, 6230 Frankfurt | 1-/1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung |
WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
US6177443B1 (en) * | 1997-03-07 | 2001-01-23 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use |
DK1009732T3 (da) | 1997-06-30 | 2003-09-22 | Merz Pharma Gmbh & Co Kgaa | 1-Amino-alkylcyclohexan NMDA receptor antagonister |
US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
DE19732589A1 (de) * | 1997-07-29 | 1999-02-04 | Huels Chemische Werke Ag | Verfahren zur Herstellung von 1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridin |
FR2769313B1 (fr) * | 1997-10-06 | 2000-04-21 | Sanofi Sa | Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese |
MXPA00004940A (es) | 1997-11-21 | 2002-10-17 | Nps Pharma Inc | Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central. |
JP4459437B2 (ja) * | 1997-12-25 | 2010-04-28 | 明治製菓株式会社 | テトラヒドロベンズインドール誘導体 |
CN1261098C (zh) | 1998-08-28 | 2006-06-28 | 西奥斯股份有限公司 | p38-α激酶的抑制剂 |
US20020049223A1 (en) | 1999-11-05 | 2002-04-25 | Elmore Steven W. | Quinoline and naphthyridine carboxylic acid antibacterials |
ATE305302T1 (de) * | 1999-12-28 | 2005-10-15 | Eisai Co Ltd | Heterozyklische verbindungen mit sulfonamid- gruppen |
GB0110338D0 (en) | 2001-04-27 | 2001-06-20 | Sb Pharmco Inc | Novel processes |
GB0118752D0 (en) * | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
CA2465326C (en) * | 2001-11-01 | 2011-03-29 | Icagen, Inc. | Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel |
US7662826B2 (en) * | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
EP1511751B1 (en) | 2002-06-04 | 2008-03-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents |
EP1581525A2 (en) * | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
EP1615697A2 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
WO2005121175A2 (en) | 2004-06-08 | 2005-12-22 | Novartis Vaccines And Diagnostics Inc. | Env polypeptide complexes and methods of use |
JP2008508337A (ja) | 2004-08-02 | 2008-03-21 | シュバルツ ファルマ アクチェンゲゼルシャフト | インドリジンカルボキサミド並びにそのアザ及びジアザ誘導体 |
EP1841766A1 (en) | 2005-01-19 | 2007-10-10 | Biolipox AB | Pyrrolopyridines useful in the treatment of inflammation |
-
2007
- 2007-08-03 AT AT07788196T patent/ATE494289T1/de active
- 2007-08-03 BR BRPI0714766-0A patent/BRPI0714766A2/pt not_active IP Right Cessation
- 2007-08-03 TW TW096128665A patent/TW200823215A/zh unknown
- 2007-08-03 CA CA002659871A patent/CA2659871A1/en not_active Abandoned
- 2007-08-03 RU RU2009107686/04A patent/RU2450004C2/ru not_active IP Right Cessation
- 2007-08-03 WO PCT/EP2007/058061 patent/WO2008015270A1/en active Application Filing
- 2007-08-03 EP EP07788197A patent/EP2054421B1/en active Active
- 2007-08-03 US US11/890,211 patent/US7947689B2/en not_active Expired - Fee Related
- 2007-08-03 EP EP10190596A patent/EP2295439A1/en not_active Withdrawn
- 2007-08-03 DK DK07788196.9T patent/DK2054416T3/da active
- 2007-08-03 JP JP2009522285A patent/JP2009545569A/ja not_active Abandoned
- 2007-08-03 CA CA002659876A patent/CA2659876A1/en not_active Abandoned
- 2007-08-03 AR ARP070103438A patent/AR062209A1/es unknown
- 2007-08-03 AU AU2007280428A patent/AU2007280428B2/en not_active Ceased
- 2007-08-03 PL PL07788196T patent/PL2054416T3/pl unknown
- 2007-08-03 DE DE602007011773T patent/DE602007011773D1/de active Active
- 2007-08-03 WO PCT/EP2007/058060 patent/WO2008015269A1/en active Application Filing
- 2007-08-03 DE DE602007010640T patent/DE602007010640D1/de active Active
- 2007-08-03 TW TW096128671A patent/TWI399376B/zh not_active IP Right Cessation
- 2007-08-03 US US11/890,199 patent/US7985753B2/en not_active Expired - Fee Related
- 2007-08-03 MX MX2009000919A patent/MX2009000919A/es active IP Right Grant
- 2007-08-03 EP EP07788196.9A patent/EP2054416B8/en active Active
- 2007-08-03 JP JP2009522284A patent/JP2010500288A/ja active Pending
- 2007-08-03 AR ARP070103437A patent/AR063680A1/es not_active Application Discontinuation
- 2007-08-03 AR ARP070103439A patent/AR062210A1/es not_active Application Discontinuation
- 2007-08-03 MX MX2009001036A patent/MX2009001036A/es active IP Right Grant
- 2007-08-03 TW TW096128661A patent/TW200815432A/zh unknown
- 2007-08-03 AT AT07788197T patent/ATE488520T1/de active
- 2007-08-03 AU AU2007280429A patent/AU2007280429A1/en not_active Abandoned
- 2007-08-03 PT PT07788196T patent/PT2054416E/pt unknown
- 2007-08-03 BR BRPI0714622-1A patent/BRPI0714622A2/pt not_active IP Right Cessation
- 2007-08-03 KR KR1020097002224A patent/KR20090047450A/ko not_active Application Discontinuation
- 2007-08-03 US US11/890,230 patent/US20080032998A1/en not_active Abandoned
- 2007-08-03 RU RU2009107688/04A patent/RU2009107688A/ru not_active Application Discontinuation
- 2007-08-03 WO PCT/EP2007/058062 patent/WO2008015271A1/en active Application Filing
-
2008
- 2008-12-15 ZA ZA2008/10605A patent/ZA200810605B/en unknown
- 2008-12-17 IL IL196008A patent/IL196008A0/en unknown
- 2008-12-17 IL IL196007A patent/IL196007A0/en unknown
-
2011
- 2011-02-23 HR HR20110128T patent/HRP20110128T1/hr unknown
- 2011-03-21 CY CY20111100303T patent/CY1112003T1/el unknown
- 2011-05-03 US US13/068,150 patent/US20110212956A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062210A1 (es) | Pirazolopirimidinas sustituidas, un proceso para su preparacion y su uso como medicamento | |
MX2007004699A (es) | Derivados de indol y bencimidazol. | |
EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
SI2134691T1 (sl) | Derivati kvinolina kot PARP in TANK inhibitorji | |
NZ596304A (en) | Substituted aminopropionic derivatives as neprilysin inhibitors | |
EP2597088A4 (en) | P2X4 Receptor Antagonists | |
PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
CL2007003821A1 (es) | Compuestos derivados de isoquinolina o isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades asociadas con la rho-quinasa y/o la fosforilacion mediada por la rho-quinasa de la cadena ligera de miosina, tales como hipertension, retinopatia, glaucoma, alzheimer, sida entre otras. | |
TW200612936A (en) | Indole derivatives | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
AR071833A1 (es) | Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades | |
CL2008001670A1 (es) | Compuestos derivados de piperidina o piperazina, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; y uso para la prevencion o tratamiento de enfermedades tales como obesidad, hipercolesterolemia, dislipidemia, entre otras. | |
EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
RS54595B1 (en) | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | |
RS53138B (en) | 4- [2- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF INJURED INTENTION SYNDROME (IBS). | |
PE20141169A1 (es) | Derivados de etinilo | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |